Journal Article

Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials

Brott, Thomas, Sandercock, Peter, Lyden, Patrick, Toni, Danilo, Bluhmki, Erich, Emberson, Jonathan, Hacke, Werner, Howard, George, Grotta, James, Lindley, Richard I, Tilley, Barbara, Kaste, Markku, Cohen, Geoff, Donnan, Geoffrey, Blackwell, Lisa, Whiteley, William, Albers, Gregory, Koga, Masatoshi, von Kummer, Ruediger, Murray, Gordon, Lansberg, Maarten, Wahlgren, Nils, Olivot, Jean Marc, Baigent, Colin, Davis, Stephen, Parsons, Mark, Toyoda, Kazunori, Lees, Kennedy R, del Zoppo, Gregory J, Wardlaw, Joanna

2014

Overview

Alteplase is effective for treatment of acute ischaemic stroke but debate continues about its use after longer times since stroke onset, in older patients, and among patients who have had the least or most severe strokes. We assessed the role of these factors in affecting good stroke outcome in patients given alteplase. We did a pre-specified meta-analysis of individual patient data from 6756 patients in nine randomised trials comparing alteplase with placebo or open control. We included all completed randomised phase 3 trials of intravenous alteplase for treatment of acute ischaemic stroke for which data were available. Retrospective checks confirmed that no eligible trials had been omitted. We defined a good stroke outcome as no significant disability at 3–6 months, defined by a modified Rankin Score of 0 or 1. Additional outcomes included symptomatic intracranial haemorrhage (defined by type 2 parenchymal haemorrhage within 7 days and, separately, by the SITS-MOST definition of parenchymal type 2 haemorrhage within 36 h), fatal intracranial haemorrhage within 7 days, and 90-day mortality. Alteplase increased the odds of a good stroke outcome, with earlier treatment associated with bigger proportional benefit. Treatment within 3·0 h resulted in a good outcome for 259 (32·9%) of 787 patients who received alteplase versus 176 (23·1%) of 762 who received control (OR 1·75, 95% CI 1·35–2·27); delay of greater than 3·0 h, up to 4·5 h, resulted in good outcome for 485 (35·3%) of 1375 versus 432 (30·1%) of 1437 (OR 1·26, 95% CI 1·05–1·51); and delay of more than 4·5 h resulted in good outcome for 401 (32·6%) of 1229 versus 357 (30·6%) of 1166 (OR 1·15, 95% CI 0·95–1·40). Proportional treatment benefits were similar irrespective of age or stroke severity. Alteplase significantly increased the odds of symptomatic intracranial haemorrhage (type 2 parenchymal haemorrhage definition 231 [6·8%] of 3391 vs 44 [1·3%] of 3365, OR 5·55, 95% CI 4·01–7·70, p<0·0001; SITS-MOST definition 124 [3·7%] vs 19 [0·6%], OR 6·67, 95% CI 4·11–10·84, p<0·0001) and of fatal intracranial haemorrhage within 7 days (91 [2·7%] vs 13 [0·4%]; OR 7·14, 95% CI 3·98–12·79, p<0·0001). The relative increase in fatal intracranial haemorrhage from alteplase was similar irrespective of treatment delay, age, or stroke severity, but the absolute excess risk attributable to alteplase was bigger among patients who had more severe strokes. There was no excess in other early causes of death and no significant effect on later causes of death. Consequently, mortality at 90 days was 608 (17·9%) in the alteplase group versus 556 (16·5%) in the control group (hazard ratio 1·11, 95% CI 0·99–1·25, p=0·07). Taken together, therefore, despite an average absolute increased risk of early death from intracranial haemorrhage of about 2%, by 3–6 months this risk was offset by an average absolute increase in disability-free survival of about 10% for patients treated within 3·0 h and about 5% for patients treated after 3·0 h, up to 4·5 h. Irrespective of age or stroke severity, and despite an increased risk of fatal intracranial haemorrhage during the first few days after treatment, alteplase significantly improves the overall odds of a good stroke outcome when delivered within 4·5 h of stroke onset, with earlier treatment associated with bigger proportional benefits. UK Medical Research Council, British Heart Foundation, University of Glasgow, University of Edinburgh.

• Publisher: Elsevier Ltd,Elsevier,Elsevier Limited
• Subject: Acute Disease / Age / Age Factors / Aged / Aged, 80 and over / Biological and medical sciences / Clinical outcomes / Clinical Trials, Phase III as Topic / Drug therapy / FDA approval / Female / Fibrinolytic Agents - administration & dosage / Fibrinolytic Agents - adverse effects / General aspects / Humans / Infusions, Intravenous / Internal Medicine / Intracranial Hemorrhages - chemically induced / Intracranial Hemorrhages - mortality / Male / Medical research / Medical sciences / Middle Aged / Mortality / Neurology / Randomized Controlled Trials as Topic / Stroke / Stroke - drug therapy / Stroke - mortality / Systematic review / Time-to-Treatment / Tissue Plasminogen Activator - administration & dosage / Tissue Plasminogen Activator - adverse effects / Treatment Outcome / Vascular diseases and vascular malformations of the nervous system